Your session is about to expire
← Back to Search
Mosunetuzumab for Aggressive B-Cell Lymphoma
Study Summary
This trial is testing mosunetuzumab as a treatment for aggressive B cell lymphomas. Mosunetuzumab is an antibody that targets T cells and cancerous B cells. The goal is to use mosunetuzumab to direct T cells to kill cancerous B cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 trial • 23 Patients • NCT04313608Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have any other cancer that could interfere with this study.My blood counts meet the required levels without recent medical help.I have been diagnosed with a specific type of aggressive lymphoma.I have had progressive multifocal leukoencephalopathy in the past.I do not have any major health issues that could interfere with the study.My lymphoma has spread to my bone marrow, but I meet specific health criteria.I have had a stem cell transplant from a donor.I can take care of myself and am up and about more than half of my waking hours.I have a history of MAS or HLH.I plan to have a stem cell transplant for my lymphoma after at least two previous treatments.I am HIV positive.I have or might have a long-term active Epstein-Barr virus infection.I have had a solid organ transplant.I have an active hepatitis B or C infection.My lymphoma did not respond to chemotherapy before my stem cell transplant.I have had severe side effects from previous immune therapy.I have not had any significant brain diseases or issues in the last 6 months.I am 18 years old or older.I have a significant history of liver disease.
- Group 1: Consolidation Mosunetuzumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What positive effects are researchers hoping to observe from this clinical trial?
"Genentech, Inc., the sponsor of this trial, has defined a primary outcome measure to be evaluated over an interval estimated at one year and thirty days. This metric is the frequency and severity of treatment-emergent adverse events (TEAEs). Additionally, secondary objectives include progression free survival (PFS), percentage of patients requiring any doses for cytokine release syndrome management with tocilizumab, as well as number of tocilizumab doses per patient for CRS management."
Are there still options for patient enrollment in this experiment?
"Clinicaltrials.gov reports that this medical trial is not currently enrolling volunteers, despite being initially posted on the 31st of December 2022 and having its information last updated on November 8th 2022. Nonetheless, there are 1,832 other trials actively recruiting patients at present."
Has Mosunetuzumab gained regulatory approval from the Food and Drug Administration?
"The safety of Mosunetuzumab has been assigned a rating of 1, as this is an early phase medical trial with only preliminary evidence to support the drug's efficacy and security."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger